Skip to content
Subscribe Follow on LinkedIn
Press Releases

Press Releases

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44

✨ Onyx Summary Avidity Biosciences reported new one-year data from the EXPLORE44 program showing that its exon 44–skipping therapy del-zota not only slowed but reversed disease progression in Duchenne muscular dystrophy patients, with improvements across multiple functional measures compared to natural history. Treatment led to sustained dystrophin production, normalization of

,   and  Press Releases
Avidity Biosciences Announces Proposed Public Offering of Common Stock

Avidity Biosciences Announces Proposed Public Offering of Common Stock

SAN DIEGO, Sept. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $500.0 million of shares of

,   and  Press Releases
Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

✨ Onyx AI Summary Guardant Health has announced a partnership with PathGroup to expand access to its FDA-approved Shield™ blood test for colorectal cancer (CRC) screening. The collaboration will bring Shield to more than 250 hospitals and health systems, 15,000+ affiliated physicians, and millions of patients across 25 states through

,   and  Press Releases
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

✨ Onyx Summary ImmunityBio reported Phase 2 data showing that ANKTIVA® (nogapendekin alfa inbakicept) can reverse therapy-induced lymphopenia in patients with checkpoint inhibitor–resistant advanced non-small cell lung cancer, with reversal linked to longer median overall survival (15.8 vs. 11.5 months; p=0.0057). The study suggests that restoring

,   and  Press Releases
Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

✨ Onyx Summary Guardant Health announced a strategic partnership with PathGroup to expand access to its FDA-approved Shield™ blood test for colorectal cancer screening across 250+ hospitals, 15,000 physicians, and millions of patients in 25 states. By integrating Shield into PathGroup’s vast network and workflows, the collaboration represents a

,   and  Press Releases
Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test

Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test

✨ Onyx Summary Guardant Health reported that its updated Shield™ colorectal cancer screening algorithm (V2) achieved 84% sensitivity and 90% specificity in a clinical validation study, including 62% sensitivity for detecting stage I disease. These results, alongside Shield’s status as the first FDA-approved blood test for CRC screening, underscore its

,   and  Press Releases
MassBio and SCbio Announce Ten Biotech and Techbio Startups to Participate in Drive Accelerator

MassBio and SCbio Announce Ten Biotech and Techbio Startups to Participate in Drive Accelerator

✨ Onyx Summary MassBio and SCbio announced the 10 startups selected for this fall’s Drive accelerator, which will run parallel biotech and techbio cohorts to support pre-seed companies tackling challenges in immunology, neuroscience, oncology, AI-driven drug discovery, and more. By equipping founders with mentorship, business tools, and investor exposure, the

,   and  Press Releases
Guardant Health to Host Investor Day on September 24, 2025

Guardant Health to Host Investor Day on September 24, 2025

✨ Onyx Summary Guardant Health will host an Investor Day on September 24, 2025, in New York City, offering a deep dive into its leadership’s vision and pipeline—an event that highlights the company’s growing influence in shaping the future of precision oncology. PALO ALTO, Calif.--(BUSINESS WIRE)

,   and  Press Releases
Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences to Participate in Upcoming Investor Conferences

✨ Onyx Summary Avidity Biosciences announced that its management team will participate in fireside chats at three upcoming investor conferences: the Cantor Global Healthcare Conference (Sept. 3), the Wells Fargo Healthcare Conference (Sept. 4), and the Morgan Stanley Global Healthcare Conference (Sept. 8). The sessions will provide updates on the company’

,   and  Press Releases
Belite Bio to Participate in Three Upcoming Investor Conferences

Belite Bio to Participate in Three Upcoming Investor Conferences

✨ Onyx Summary Belite Bio announced that its executive team will present at three major upcoming investor conferences in early September, including Cantor, Morgan Stanley, and H.C. Wainwright. Each presentation will be webcast and available for replay on the company’s investor relations website. These appearances highlight growing investor interest

,   and  Press Releases
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

✨ Onyx Summary ImmunityBio announced early pilot data in recurrent glioblastoma showing that all five patients treated with its combination of ANKTIVA® (an IL-15 agonist), NK cell therapy, and Optune Tumor Treating Fields achieved disease control, including two near-complete responses. Glioblastoma is among the most aggressive brain cancers, with limited treatment

,   and  Press Releases
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

✨ Onyx Summary Phathom Pharmaceuticals announced that its management team will present at the Cantor Global Healthcare Conference on September 3 and the H.C. Wainwright Global Investment Conference on September 8, 2025, with live webcasts and replays available on the company’s website. Management will also participate in one-on-one investor

,   and  Press Releases